JP2005509432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509432A5 JP2005509432A5 JP2003545801A JP2003545801A JP2005509432A5 JP 2005509432 A5 JP2005509432 A5 JP 2005509432A5 JP 2003545801 A JP2003545801 A JP 2003545801A JP 2003545801 A JP2003545801 A JP 2003545801A JP 2005509432 A5 JP2005509432 A5 JP 2005509432A5
- Authority
- JP
- Japan
- Prior art keywords
- allele
- nucleic acid
- disease
- isolated nucleic
- contiguous nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028369 Alleles Proteins 0.000 claims 29
- 108020004707 nucleic acids Proteins 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 19
- 102100039065 Interleukin-1 beta Human genes 0.000 claims 19
- 238000000034 method Methods 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 108010002352 Interleukin-1 Proteins 0.000 claims 10
- 102000000589 Interleukin-1 Human genes 0.000 claims 8
- 208000027866 inflammatory disease Diseases 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 5
- 230000016396 cytokine production Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000054766 genetic haplotypes Human genes 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33168101P | 2001-11-19 | 2001-11-19 | |
| US38602002P | 2002-06-05 | 2002-06-05 | |
| PCT/US2002/037222 WO2003044176A2 (en) | 2001-11-19 | 2002-11-19 | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260743A Division JP2010029220A (ja) | 2001-11-19 | 2009-11-16 | 転写および炎症性疾患および感染症に対する感受性に影響するインターロイキン−１遺伝子座の機能的多型 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005509432A JP2005509432A (ja) | 2005-04-14 |
| JP2005509432A5 true JP2005509432A5 (enExample) | 2006-01-12 |
| JP4492849B2 JP4492849B2 (ja) | 2010-06-30 |
Family
ID=26987865
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545801A Expired - Lifetime JP4492849B2 (ja) | 2001-11-19 | 2002-11-19 | 転写および炎症性疾患および感染症に対する感受性に影響するインターロイキン−１遺伝子座の機能的多型 |
| JP2009260743A Pending JP2010029220A (ja) | 2001-11-19 | 2009-11-16 | 転写および炎症性疾患および感染症に対する感受性に影響するインターロイキン−１遺伝子座の機能的多型 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260743A Pending JP2010029220A (ja) | 2001-11-19 | 2009-11-16 | 転写および炎症性疾患および感染症に対する感受性に影響するインターロイキン−１遺伝子座の機能的多型 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030235890A1 (enExample) |
| EP (1) | EP1463745A4 (enExample) |
| JP (2) | JP4492849B2 (enExample) |
| KR (2) | KR101019131B1 (enExample) |
| CN (2) | CN101955943A (enExample) |
| AU (1) | AU2002359431A1 (enExample) |
| CA (1) | CA2467717A1 (enExample) |
| WO (1) | WO2003044176A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| BR0314552A (pt) * | 2002-09-30 | 2005-08-09 | Novartis Ag | Métodos para prognosticar elevações de colesterol durante terapia imunossupressora |
| US20050175721A1 (en) * | 2004-02-06 | 2005-08-11 | Brovelli Ernesto A. | Method of augmenting the immune-modulatory activity of standardized Echinacea preparations |
| WO2005082070A2 (en) * | 2004-02-26 | 2005-09-09 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
| ES2356167T3 (es) * | 2004-05-03 | 2011-04-05 | Interleukin Genetics, Inc. | Método de diagnóstico y terapia para enfermedades asociadas con un haplotipo inflamatorio il-1. |
| EP1795886A4 (en) * | 2004-08-24 | 2010-04-07 | Fujifilm Corp | METHOD FOR CALCULATING THE DISSOCIATION CONSTANT IN SURFACE PLASMON RESONANCE ANALYSIS |
| JP2006262826A (ja) * | 2005-03-25 | 2006-10-05 | Institute Of Physical & Chemical Research | インターロイキン−１受容体２遺伝子の多型に基づく炎症性疾患の検査法 |
| US8105775B2 (en) | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| JP4870976B2 (ja) * | 2005-11-10 | 2012-02-08 | 株式会社Ｄｎａチップ研究所 | 全血を用いた自己免疫疾患の検査方法 |
| WO2008060627A2 (en) | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| US20090170105A1 (en) * | 2007-11-08 | 2009-07-02 | Interleukin Genetics, Inc. | Diagnostics for Aging-Related Dermatologic Disorders |
| CA3011363A1 (en) | 2016-01-12 | 2017-07-20 | Interleukin Genetics, Inc. | Methods for predicting response to treatment |
| KR102543907B1 (ko) * | 2016-06-17 | 2023-06-15 | 서울대학교산학협력단 | 치주질환 위험도 평가용 유전자 마커 |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| JP7097855B2 (ja) * | 2019-04-24 | 2022-07-08 | ジェネシスヘルスケア株式会社 | 歯周病のリスクを判定する方法 |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
| WO2022040090A1 (en) * | 2020-08-17 | 2022-02-24 | The Regents Of The University Of California | Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| US4998617A (en) * | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US4968607A (en) * | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5459039A (en) * | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US5593826A (en) * | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5686246A (en) * | 1995-08-03 | 1997-11-11 | Kornman; Kenneth S. | Detecting genetic predisposition to periodontal disease |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US5698399A (en) * | 1996-04-05 | 1997-12-16 | Duff; Gordon W. | Detecting genetic predisposition for osteoporosis |
| GB9621129D0 (en) * | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| US6210877B1 (en) | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| US6437216B1 (en) * | 1997-11-13 | 2002-08-20 | Interleukin Genetics Inc. | Transgenic models of inflammatory disease |
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| JP2003508022A (ja) * | 1999-06-30 | 2003-03-04 | インターリューキン ジェネティックス インコーポレイテッド | Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法 |
| HK1046688A1 (zh) * | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US8071304B2 (en) * | 2003-04-05 | 2011-12-06 | The Johns Hopkins University | Methods for detecting a polymorphism in the NFKB1 gene promoter |
-
2002
- 2002-11-19 EP EP02793968A patent/EP1463745A4/en not_active Withdrawn
- 2002-11-19 KR KR1020047007653A patent/KR101019131B1/ko not_active Expired - Fee Related
- 2002-11-19 WO PCT/US2002/037222 patent/WO2003044176A2/en not_active Ceased
- 2002-11-19 AU AU2002359431A patent/AU2002359431A1/en not_active Abandoned
- 2002-11-19 KR KR1020107016833A patent/KR101059898B1/ko not_active Expired - Fee Related
- 2002-11-19 JP JP2003545801A patent/JP4492849B2/ja not_active Expired - Lifetime
- 2002-11-19 CN CN201010156318.0A patent/CN101955943A/zh active Pending
- 2002-11-19 CN CN02827282.XA patent/CN1753903B/zh not_active Expired - Fee Related
- 2002-11-19 CA CA002467717A patent/CA2467717A1/en not_active Abandoned
- 2002-11-19 US US10/300,011 patent/US20030235890A1/en not_active Abandoned
-
2008
- 2008-03-13 US US12/048,077 patent/US20100279280A1/en not_active Abandoned
-
2009
- 2009-11-16 JP JP2009260743A patent/JP2010029220A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509432A5 (enExample) | ||
| Wu et al. | Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population | |
| JP2012503985A5 (enExample) | ||
| Lo et al. | Association of SNPs and haplotypes in GABAA receptor β2 gene with schizophrenia | |
| Drtilkova et al. | Clinical and molecular-genetic markers of ADHD in children | |
| AU2009224170A1 (en) | Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using SNP array | |
| Oostenbrug et al. | CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis | |
| JP2010510804A5 (enExample) | ||
| JP2006521812A5 (enExample) | ||
| Kanno et al. | Association between nonsyndromic cleft lip with or without cleft palate and the glutamic acid decarboxylase 67 gene in the Japanese population | |
| JP2007501627A5 (enExample) | ||
| MX2007014220A (es) | Metodos para la valoracion del riesgo de desarrollar cancer de pulmon usando un analisis de polimorfismos geneticos. | |
| Palmieri et al. | CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing | |
| Manchanda et al. | Correlation between a gene polymorphism of tumor necrosis factor-α (G/A) and end-stage renal disease: A pilot study from north India | |
| JP2010525788A (ja) | 心臓血管機能及び障害の評価のための方法及び組成物 | |
| Lucotte et al. | Polymerase chain reaction detection of S and Z alpha-1-antitrypsin variants by duplex PCR assay | |
| WO2009055596A2 (en) | Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits | |
| KR101992952B1 (ko) | 콜레스테롤 유출능과 관련된 심혈관질환의 발병 위험을 예측하기 위한 조성물, 키트, 및 이를 이용한 방법 | |
| KR102883401B1 (ko) | 우울증 진단용 단일염기다형성 및 이의 용도 | |
| EP2566978A1 (en) | Antiviral treatment susceptibility gene and uses thereof | |
| KR102751989B1 (ko) | 뇌동맥류 진단용 rs3120004 마커 조성물 및 이의 이용 | |
| KR102751988B1 (ko) | 뇌동맥류 진단용 rs7779989 마커 조성물 및 이의 이용 | |
| KR101167945B1 (ko) | Ａｔｇ16ｌ1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 자폐 스펙트럼 장애 분석방법 | |
| KR102751993B1 (ko) | 뇌동맥류 진단용 rs2440154 마커 조성물 및 이의 이용 | |
| Kim et al. | Usefulness of direct sequencing of pooled DNA for SNP identification and allele-frequency determination compatible with a common disease/common variant hypothesis |